# C-RAD > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/c-radb). ## Overview C-RAD is a Swedish medical technology company focused on surface-guided radiotherapy systems for cancer treatment. Its portfolio includes positioning, imaging and workflow solutions, plus service and support offerings sold to hospitals, clinics and distributors worldwide through the C-RAD group. ## Products & services • Surface-guided radiotherapy (SGRT) systems • Patient positioning and monitoring solutions • Imaging and workflow software • Service, maintenance and upgrades • Clinical training and consultancy • Laser and related positioning products - **Positioning systems** (55%) — Hardware and software used to position patients precisely during radiotherapy. - **Imaging systems** (10%) — Imaging and surface-scanning solutions that support treatment setup and monitoring. - **Service and support** (25%) — Maintenance, upgrades, long-term contracts and technical support for installed systems. - **Clinical training and consultancy** (5%) — Training and advisory services that help clinics use the systems effectively. - **Distribution and other products** (5%) — Third-party or ancillary product sales and related offerings. - Surface-guided radiotherapy (SGRT) systems - Patient positioning and monitoring solutions - Imaging and workflow software - Service, maintenance and upgrades - Clinical training and consultancy - Laser and related positioning products ## Customers C-RAD sells primarily to hospitals, cancer clinics and radiotherapy centers that need precise patient positioning and workflow support. It also works through distributors and local partners, which extends reach into markets where direct sales are less practical. The buying decision is driven by clinical accuracy, patient safety, workflow efficiency and the need for ongoing service support. - **Public hospitals and cancer clinics** (primary) — Buy SGRT and positioning systems for radiotherapy departments that need precision and safety. - **Private oncology clinics** (secondary) — Buy systems and service packages to improve treatment workflow and patient experience. - **Reference clinics** (secondary) — Adopt and validate new workflows, helping support broader market acceptance. - **Distributors and channel partners** (secondary) — Purchase or resell products in markets served indirectly by C-RAD. - **Installed-base service customers** (primary) — Buy maintenance, upgrades and training for existing C-RAD systems. - Public cancer clinics and hospitals purchasing radiotherapy equipment - Private oncology centers seeking precision and workflow efficiency - Reference clinics that validate clinical use and adoption - Distributors and partners that resell into local markets - Clinics buying service contracts, upgrades and training ## Geography C-RAD sells globally, with products manufactured in Finland and distributed through direct sales and local partners. Reported revenue has been split across the Americas, EIMEA and APAC, showing a broad international footprint rather than dependence on one market. Geography matters because healthcare purchasing cycles, reimbursement systems and distributor coverage vary by region. - **Americas** (20.8%) — Based on Q1 2020 revenue per geographical market - **EIMEA** (51.7%) — Europe, India, Middle East and Africa combined in company reporting - **APAC** (27.7%) — Asia-Pacific regional reporting bucket - Products are manufactured in Finland - Sales are global through direct channels and distributors - Revenue is spread across the Americas, EIMEA and APAC - Installed base worldwide supports recurring service revenue - Regional healthcare budgets affect order timing and demand ## Strategy C-RAD’s strategy centers on expanding sales in established and new markets, investing in product development and broadening its service offering. A larger installed base is important because it increases recurring revenue from service, upgrades and training, which strengthens customer relationships and supports a more stable business model. - **International expansion** (medium-term) — Broader market coverage reduces dependence on a few regions and supports growth. - **Service revenue growth** (short-term) — Recurring contracts improve customer retention and create a more stable revenue base. - **Product development** (medium-term) — New and improved systems help maintain relevance in a technology-driven niche. - **Operational execution** (short-term) — Reliable delivery and implementation are critical in a project-based medical device business. - Expand direct sales and distributor coverage in international markets - Invest in product development for precision radiotherapy workflows - Grow service, maintenance and upgrade revenue from the installed base - Improve execution and delivery predictability across the organization - Strengthen recurring revenue to deepen customer relationships ## Risks C-RAD faces execution risk because demand spikes or slower-than-expected deliveries can disrupt order conversion and customer relationships. It is also exposed to foreign exchange, credit, liquidity, cyber security and partner-dependence risks, while competition and technology shifts can pressure market share in radiotherapy equipment. - **Delivery and capacity constraints** [high] — Rapid order growth or uneven demand can overwhelm planning, manufacturing and installation resources. - **Dependence on external partners** [high] — Sales in some markets rely on distributors and cooperation agreements that may fail or change. - **Foreign exchange risk** [medium] — Revenue and costs are spread across currencies, creating translation and transaction exposure. - **Cyber security risk** [medium] — The business depends on data, software and connected clinical workflows that must remain secure. - **Competition in radiotherapy technology** [medium] — Larger competitors or adjacent players could invest heavily and pressure pricing or adoption. - Demand swings can strain delivery capacity and planning - Reliance on distributors and cooperation partners can limit control - Currency movements affect international sales and costs - Cyber security incidents could disrupt systems and reputation - Competition from larger medtech players can erode share ## Accounting C-RAD’s results are affected by revenue timing because products are recognized when delivered, while service contracts are recognized over the contract period. The company also has meaningful judgment areas around order backlog, lease accounting, deferred tax assets, impairment testing and contingent liabilities, all of which can affect reported assets, liabilities and earnings. - **Revenue recognition for products and services** — Delivery timing and contract duration - **Order backlog accounting** — Visibility into future revenue conversion - **Deferred tax assets** — Balance sheet and tax expense - **Impairment testing** — Potential write-downs if assumptions weaken - **Lease accounting** — Balance sheet and EBITDA presentation - **Contingent liabilities** — Potential future cash outflows - Product revenue is recognized on delivery, affecting quarterly timing - Service contracts are recognized over time across the contract period - Order backlog includes undelivered products and service contracts - Deferred tax assets depend on expected future taxable profits - Lease and impairment judgments affect assets and operating results --- *Last updated: 2026-08-11T04:04:51.417279+00:00*